

Created by the AC Forum, this order set offers a template for reversal and hemostatic therapies for adults with DOAC-related, life-threatening bleeding. To be used once decision has been made to reverse anticoagulation. Use as a primary document or integrate decision-making into your EMR system. January 2023.
Authors: Ronni Nemeth, PharmD, CACP, DPLA; Scott Kaatz, DO, MSc; Kyle DeWitt, PharmD, BCPS; Deb Siegal, MD, MSc, FRCPC
This content was developed independently by the Anticoagulation Forum. Support for this project provided by AstraZeneca.
This is an order set including risk assessment, drug selection, initiation & dosing, labs, patient education & other considerations. Use it as a primary document or to integrate decision-making into your EMR system.
You can also view a webinar discussing this order set with authors Dr. Geoff Barnes, Dr. Scott Kaatz, Eva Kline Rogers and Stacy Ellsworth.
Created by the AC Forum, this order set includes factors for drug selection, dosing, DOAC and non-DOAC therapies, kidney and liver function labs, as well as shared decision-making and other considerations.
This order set may be used for adult patients diagnosed with venous thromboembolism who are ready to be transferred from the hospital or emergency department to outpatient care settings. Use this as a primary document or to integrate decision-making into your EMR system.
This order set may be used for patients diagnosed with stable coronary artery disease (CAD) and/or peripheral artery disease (PAD) who are already being treated with guideline directed antiplatelet therapy and require prescription of adjunct direct oral anticoagulant therapy in an inpatient or outpatient setting.
This order set is intended to facilitate standardized venous thromboembolism (VTE) prophylaxis risk stratification of hospitalized medically ill patients for: